| __timestamp | Bristol-Myers Squibb Company | Pfizer Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 14097000000 |
| Thursday, January 1, 2015 | 5001000000 | 14809000000 |
| Friday, January 1, 2016 | 5002000000 | 14837000000 |
| Sunday, January 1, 2017 | 4849000000 | 14784000000 |
| Monday, January 1, 2018 | 4551000000 | 14455000000 |
| Tuesday, January 1, 2019 | 4871000000 | 14350000000 |
| Wednesday, January 1, 2020 | 7661000000 | 11615000000 |
| Friday, January 1, 2021 | 7690000000 | 12703000000 |
| Saturday, January 1, 2022 | 7814000000 | 13677000000 |
| Sunday, January 1, 2023 | 7772000000 | 14771000000 |
| Monday, January 1, 2024 | 8414000000 | 14730000000 |
Cracking the code
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Pfizer Inc. and Bristol-Myers Squibb Company have showcased contrasting strategies in this domain. From 2014 to 2023, Pfizer consistently reported higher SG&A expenses, peaking at approximately $14.8 billion in 2016. In contrast, Bristol-Myers Squibb maintained a more conservative approach, with expenses fluctuating between $4.6 billion and $7.8 billion.
Despite Pfizer's larger scale, Bristol-Myers Squibb's ability to keep SG&A costs relatively stable, even during challenging years like 2020, highlights their efficiency. Notably, Pfizer's expenses saw a significant dip in 2020, aligning with global economic shifts. As these giants continue to evolve, their SG&A strategies will remain pivotal in shaping their financial health and competitive edge.
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
Selling, General, and Administrative Costs: Pfizer Inc. vs Vertex Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: Pfizer Inc. vs GSK plc
Who Optimizes SG&A Costs Better? Pfizer Inc. or Pharming Group N.V.
SG&A Efficiency Analysis: Comparing Pfizer Inc. and Rhythm Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Pfizer Inc. or Catalyst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Pfizer Inc. vs Mesoblast Limited
Breaking Down SG&A Expenses: Pfizer Inc. vs Dynavax Technologies Corporation
Bristol-Myers Squibb Company or Zoetis Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.